Objective: The aim of the study was to determine the association between self-reported vasomotor symptoms (VMS) and obstructive sleep apnea (OSA) risk.
T he menopausal transition is independently associated with poor sleep [1] [2] [3] and seems to be associated with increased risk for obstructive sleep apnea (OSA). [4] [5] [6] [7] In addition, up to 80% of midlife women experience hot flashes or night sweats (vasomotor symptoms-VMS). 8 Although there is an association between the presence of VMS and sleep disturbances in midlife women, it may be clinically difficult to distinguish sleep disturbances directly related to menopausal symptoms from those due to an underlying primary sleep disorder such as OSA. 9, 10 Although OSA is more common in men than women, the risk for OSA in women increases with age, obesity, and periand postmenopause status. 11, 12 For example, the prevalence of OSA increases from 6.5% in women in their 30s to 16% in women in their 50s. 13 In a sample of peri-and postmenopausal women who experienced disturbed sleep, 53% were found to have a primary sleep disorder (OSA, restless leg syndrome or both). 10 The Sleep in Midlife Women Study also found that progression through the menopausal transition was associated with increasing severity of sleep disordered breathing.
METHODS
The Women's Health Clinic (WHC) at Mayo Clinic, Rochester, MN, is a subspecialty clinic that provides consultative care to women presenting with menopausal symptoms or sexual health concerns. Women seen in the WHC between May 2015 and December 2016 provided self-reported responses to the Menopause Rating Scale (MRS) and the STOP-BANG questionnaires as part of their clinical visit. Responses to these questionnaires are contained in a database called Data Registry on Experiences of Aging, Menopause and Sexuality (DREAMS). For the purposes of this study, only midlife women between the ages of 40 and 65 years were included in the analysis. Additional information about body mass index (BMI), current tobacco use, education, relationship status, employment status, race/ethnicity, menopause status, menopausal hormone therapy use, and diagnoses of sleep disorders (using ICD codes) was obtained from the electronic medical record. Women provided written, informed consent for the use of their medical records for research purposes.
The MRS assesses the presence and severity of menopausal symptoms with 11 questions, each rated on a scale of 0 to 4 for severity (0 ¼ none; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe; 4 ¼ very severe). In addition to total MRS score, the questions assessing hot flashes/sweating and sleep problems (difficulty falling asleep, difficulty sleeping through the night, waking up early) were assessed individually.
OSA risk was assessed with the STOP-BANG questionnaire, which consists of eight questions with self-reported yes/ no answers to Snoring, Tired, Observed apneas, Pressure (hypertension), Body mass index >35 kg/m 2 , and numerical responses to Age, Neck size, and categorical response to Gender. Based on studies which included both men and women, the STOP-BANG has a high sensitivity of 87% and modest specificity of 43% for detection of moderate to severe OSA, which increases the risk of false positive screening results. 29 As sensitivity and specificity data for the questionnaire are not available for women, for the purposes of the present study, scores were derived according to published formulation: low risk ¼ yes to 0 to 2 questions; intermediate risk ¼ yes to 3 to 4 questions; high risk ¼ yes to 5 to 8 questions or yes to 2 or more STOP questions and BMI >35 kg/m 2 . 30 Unless otherwise specified, data are presented using mean AE SD for continuous variables, and frequency percentages for categorical variables. The intermediate and high-risk groups were combined to compare with the low-risk group for a binary variable indicating OSA risk (yes vs no).
The answers to the individual MRS questions pertaining to hot flashes/sweating and sleep problems were grouped to produce binary variables: moderate/severe/very severe versus none/mild; severe/very severe versus none/mild/moderate. Univariate logistic regression was then performed with OSA risk as the dependent variable, and demographics or MRS measures as the explanatory variable. Multivariable logistic regression was used to assess the association between OSA risk and MRS measures after adjusting for age, smoking, and BMI.
All statistical tests were two-sided and the threshold statistical significance was set at P < 0.05. All analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC). VASOMOTOR SYMPTOMS AND SLEEP APNEA RISK DISCUSSION In this large cross-sectional cohort of midlife women, total MRS scores and self-reported severe and very severe VMS ratings were significantly associated with intermediate/high risk for OSA as assessed by the highly sensitive, moderately specific STOP-BANG screening tool that may overestimate OSA risk. The nature of this association is unclear, but shared risks such as age, smoking status, and BMI do not fully account for the association because the findings persist after adjusting for these factors. Furthermore, an association between severe/very severe VMS and intermediate/high OSA risk persisted in subgroup analysis of women with BMI <25 kg/m 2 . This relationship most likely reflects interactions among neuronal circuits associated with temperature regulation (as might be related to vasomotor symptoms), those regulating sleep, and those controlling respiration as well as alterations in peripheral or central chemosensor sensitivity and their modulation by hormone status (eg, levels of estrogen, progesterone, or follicle-stimulating hormone). 31, 32 Different patterns of VMS have been described in postmenopausal women, 33 suggesting differences in neurovascular dysregulation or perhaps more general autonomic dysregulation that warrants further investigation. Consistent with population-based data, 11 about one-quarter (24.9%) of women in our cohort were at intermediate/high risk for OSA. An important finding of this study is that 65% of women in the intermediate/high-risk OSA group remained without a diagnosis of OSA up to 2 years after their clinical consultation, which is also consistent with population-based data regarding the underdiagnosis of OSA in women. 11 Our results underscore the importance of having a high level of clinical suspicion for the presence of OSA in postmenopausal women, particularly given the significant morbidity and mortality associated with untreated disease. 34 For example, in a study of 207 pre-and postmenopausal women that assessed hypertension prevalence, BMI was the only factor that affected the blood pressure profile in premenopausal women, whereas both BMI and apnea hypopnea index affected the blood pressure profile in postmenopausal women. 35 Another study of 277 midlife women concluded that OSA is underdiagnosed and independently associated with hypertension and increased arterial stiffness in perimenopausal women. 36 The results of the present study suggest that the intensity of VMS might be a factor that links OSA and increased cardiovascular risk in postmenopausal women, thereby alerting the clinician to the need for further evaluation.
RESULTS

Of
The conclusion that VMS may alert clinicians to increased cardiovascular risk is not new. Indeed, in a large population-based study involving 11,725 midlife women VASOMOTOR SYMPTOMS AND SLEEP APNEA RISK followed for 14 years, those reporting frequent VMS had an increased risk for incident CHD compared with those who did not, even after adjusting for multiple factors including age, menopause status, lifestyle, BMI, diabetes, and hypertension. 37 Reduced flow-mediated vasodilatation was also associated with VMS in recent (<10 y from last menstrual period) and late (>10 y from last menstrual period) postmenopause phases in one study, 38 but only among younger midlife women in another study. 20 In the Women's Ischemia Syndrome Evaluation (WISE) study, women with early onset VMS (first occurring before the age of 42 y) had lower flowmediated dilatation and higher cardiovascular mortality than those who experienced later onset VMS. 21 Overall, the aggregate data support an association between VMS and CHD risk, 39, 40 with a suggestion that night sweats more than daytime hot flashes may be associated with increases in blood pressure. 41, 42 The STOP-BANG self-report was used in the present study to assess OSA risk. Although in a community-based sample STOP-BANG is sensitive (87%) for detection of moderate-tosevere OSA in both men and women, the specificity is modest (43%) for detection of moderate-to-severe OSA and increases the risk of false-positive screening results. 29 In individuals with midrange STOP-BANG scores (at lower risk for moderate-to-severe OSA), the specificity for OSA at any level is increased when combined with BMI !35 kg/m 2 . 30 These studies may, however, not be entirely applicable to women as the Sleep Heart Health Study showed that weight changes led to more significant changes in apnea hypopnea index in men than women. 43 In addition, several studies have validated versions of the STOP-BANG in specific populations, including those of Chinese, Indian, and Danish descent, in whom BMI tends to be lower than in the US population. [44] [45] [46] [47] [48] Yet, even at a lower BMI, the STOP-BANG remains a sensitive screening tool. 47, 48 Although it is clear that menopausal hormone therapy (MHT) is helpful for VMS management and may mitigate CHD risk in younger postmenopausal women, 49 the question of whether there is a role for MHT in the management of OSA or sleep disordered breathing in menopausal women is still unanswered. One study demonstrated that the prevalence of OSA was greater in postmenopausal women who did not receive MHT compared with premenopausal women and postmenopausal women on MHT. 12 Estrogen and 
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progesterone have been associated with increased sensitivity to hypercapnia and hypoxia, whereas ovariectomy has been associated with decreased sensitivity to hypoxia. [50] [51] [52] One prospective randomized controlled trial investigating the impact of estrogen on sleep-related disordered breathing revealed that 3 months of unopposed transdermal estradiol was associated with decreased occurrence (P ¼ 0.047) and frequency (P ¼ 0.049) of sleep apnea in healthy postmenopausal women, but had no effect on partial upper airway obstruction. 53 Furthermore, lower estradiol levels were shown to be associated with increased OSA risk in a study of 30 depressed peri/postmenopausal women. 6 Another small study involving nine postmenopausal women showed that treatment with conjugated equine estrogens and medroxyprogesterone acetate was associated with reduced risk of sleep-related disordered breathing. 54 Given the lack of randomized controlled clinical trial data, no definitive conclusions can, however, be made regarding the role of MHT for management of OSA or sleep-related disordered breathing.
To the best of our knowledge, this hypothesis generating study is the first to examine the association between VMS and OSA in midlife women. The strength of the study is the relatively large size of our cohort. As this is a cross-sectional study, causality cannot be determined. A potential limitation of this study is the lack of racial diversity in the cohort as the majority of women were white, educated, married, and employed, thus limiting the generalizability of the findings to other ethnic and socioeconomic groups. In addition, the MRS does not distinguish between daytime and nighttime symptoms, and distinguishing between the two may be helpful to identify women who are experiencing sleep disruption due to OSA and who may be more aware of nighttime VMS. The STOP-BANG questionnaire may underestimate risk for OSA in some women as the question about witnessed apneic events may not be accurate in women without bed partners, and 20% of participants did not know their neck size.
Although the STOP-BANG questionnaire has not been validated in women as a specific subpopulation, the validation studies for this tool have included large numbers of women. One study compared STOP-BANG with three other OSA screeners in a community-based sample of 4,770 individuals, 48.5% of whom were women, and found that STOP-BANG had the highest sensitivity in predicting moderate and severe sleep disordered breathing. 29 Several studies have shown that the STOP-BANG tool has high sensitivity and moderate specificity and thus may overestimate OSA risk. Although sex-specific data are not available, studies involving more women than men have supported this conclusion. [55] [56] [57] In addition, VMS were self-reported and subjective rather than objectively measured, and thus subject to recall bias. We do not have specific information on which menopausal symptom caused women to seek care in the Women's Health Clinic (eg, VMS or sleep disturbance), which may have biased the findings. Also, we did not have access to data regarding referrals for additional testing to confirm the diagnosis of sleep-disordered breathing or for treatment.
CONCLUSIONS
The results of the present study suggest that women reporting severe or very severe VMS in midlife may be at higher risk for OSA, particularly those with hypertension and obesity. Furthermore, this risk is often unrecognized. An association between severe/very severe VMS and high OSA risk persisted in subgroup analysis of women with BMI <25 kg/m 2 after adjustment for age and smoking status, suggesting the possibility that factors other than obesity may be contributing to this association. Given the low specificity of STOP-BANG in mixed populations of men and women and the lack of validation in women as a specific population, a critical need exists for a brief, validated screening tool that can be used for clinical assessment of women.
Both VMS and OSA are associated with cardiovascular risk, 58 and increased clinical visibility of these associations is necessary to facilitate evaluation for and treatment of OSA in midlife women. It is important to note that not all sleep disturbances in midlife women directly relate to VMS, and primary sleep disorders may coexist. Distinguishing between sleep disturbances secondary to OSA versus those predominantly related to VMS is critical to determine appropriate treatment in women.
